Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Tuberculosis
Interventions
DRUG

Ibuprofen

Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy

DRUG

Standard of Care TB treatment

Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.

Trial Locations (2)

Unknown

National Center for Tuberculosis and Lung Diseases, Tbilisi

1862,

Perinatal HIV Unit (PHRU), Soweto

All Listed Sponsors
collaborator

National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia

OTHER

lead

Fundació Institut Germans Trias i Pujol

OTHER

NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis | Biotech Hunter | Biotech Hunter